[Clinico-biochemical aspects of the polychemotherapy of disseminated lymphogranulomatosis resistant to the COPP protocol].
With a purpose of providing efficient treatment of extended lymphogranulomatosis resistant to the routine COPP program, new programs of polychemotherapy including the use of an antibiotic, plant alkaloid, alkylating agent and glucocorticoid were developed and studied. The optimal rhythm and regimen of the drug administration were developed. The study was based on the treatment of 65 patients. The clinical trials showed that the ALVP program including the use of adriablastin, lofenal, vinblastin and prednisolone was the most efficient. Its use provided a significant therapeutic effect in 77 per cent of the patients. The BrLVP program including the use of bruneomycin, lofenal, vinblastin and prednisolone, the RLVP program including the use of rubomycin, lofenal, vinblastin and prednisolone, the DLVP program including the use of dactinomycin, lofenal, vinblastin and prednisolone and the BlLVP program including the use of bleomycin, lofenal, vinblastin and prednisolone were less efficient and provided the therapeutic effect in 66, 63, 60 and 60 per cent of the patients respectively. The direction of shifts in the spectrum of the blood serum enzymes mainly corresponded to the results of clinical trials. This first of all referred to the ALVP and BrLVP programs. The use of these programs provided normalization of the hexokinase and lactate dehydrogenase activity of the serum and positive shifts in the isoenzyme spectrum.
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors; D004341:Drug Evaluation; D004351:Drug Resistance; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D008875:Middle Aged; D011241:Prednisone / Q000037:antagonists & inhibitors; D011344:Procarbazine / Q000037:antagonists & inhibitors; D013997:Time Factors; D014750:Vincristine / Q000037:antagonists & inhibitors
D000903:Antibiotics, Antineoplastic; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone
Kliniko-biokhimicheskie aspekty polikhimioterapii rasprostranennogo limfogranulematoza, rezistentnogo k programme TsOPP.